Distribution of patients by source and dose of nucleated cells/kg infused
. | BM . | . | . | P . | . | ||
|---|---|---|---|---|---|---|---|
. | NC less than 2.7 × 108/kg, n = 258 . | NC more than 2.7 × 108/kg, n = 257 . | PB, n = 366 . | BM more than 2.7 vs BM less than 2.7 × 108/kg . | PB vs BM less than 2.7 × 108/kg . | ||
| Year of BMT (range) | 1996 (1994-2000) | 1996 (1994-2000) | 1998 (1994-2001) | .03 | < .0001 | ||
| Age, y (range) | |||||||
| Patients | 36 (16-58) | 37 (16-57) | 37 (16-66) | .25 | .04 | ||
| Donors | 35 (5-65) | 35 (10-59) | 37 (14-67) | .81 | .008 | ||
| Patient sex (%) | |||||||
| Male | 138 (53) | 126 (49) | 189 (52) | ||||
| Female | 120 (46) | 130 (51) | 174 (48) | .33 | .73 | ||
| Donor sex (%) | |||||||
| Male | 128 (51) | 146 (58) | 203 (56) | ||||
| Female | 124 (49) | 104 (42) | 162 (44) | .08 | .24 | ||
| Female donor to male recipient, % | 27 | 18 | 24 | .02 | .43 | ||
| White blood cell count at diagnosis, × 109/L | 11 (0.2-420) | 10.6 (0.7-500) | 13.5 (0.7-710) | .57 | .49 | ||
| FAB classification (%) | |||||||
| M0 | 3 (1) | 1 (0.4) | 3 (1) | ||||
| M1 | 46 (20) | 53 (23) | 52 (16) | ||||
| M2 | 67 (29) | 84 (36) | 111 (34) | ||||
| M3 | 13 (5) | 9 (4) | 11 (3) | .23 | .66 | ||
| M4 | 58 (25) | 46 (20) | 81 (25) | ||||
| M5 | 37 (16) | 29 (12) | 52 (16) | ||||
| M6 | 6 (2) | 10 (4) | 13 (4) | ||||
| M7 | 4 (2) | 1 (0.4) | 4 (1) | ||||
| Cytogenetics, n (%) | n = 125 | n = 115 | n = 126 | — | — | ||
| Good | 21 (17) | 15 (13) | 21 (17) | — | — | ||
| Intermediate | 95 (76) | 93 (81) | 96 (76) | — | — | ||
| Poor | 9 (7) | 7 (6) | 9 (7) | .65 | 1 | ||
| Interval diagnosis-CR1, d (range) | 40 (12-305) | 43 (17-480) | 41 (17-432) | .34 | .96 | ||
| Interval CR1-transplantation, d (range) | 99 (13-369) | 94 (11-2375) | 97 (12-594) | .29 | .37 | ||
| TBI, % | 45 | 57 | 37 | .005 | .06 | ||
| NCs infused, × 108/kg (range) | 2 (0.17-2.7) | 3.68 (2.7-29) | 9.3 (2.2-77) | — | — | ||
| aGVHD grades II-IV, % | 38 | 35 | 36 | .5 | .61 | ||
| aGVHD grades III-IV, % | 13 | 9 | 12 | .18 | .64 | ||
| Follow-up, mo (range) | 33 (1-79) | 35 (1-81) | 16 (1-72) | — | — | ||
. | BM . | . | . | P . | . | ||
|---|---|---|---|---|---|---|---|
. | NC less than 2.7 × 108/kg, n = 258 . | NC more than 2.7 × 108/kg, n = 257 . | PB, n = 366 . | BM more than 2.7 vs BM less than 2.7 × 108/kg . | PB vs BM less than 2.7 × 108/kg . | ||
| Year of BMT (range) | 1996 (1994-2000) | 1996 (1994-2000) | 1998 (1994-2001) | .03 | < .0001 | ||
| Age, y (range) | |||||||
| Patients | 36 (16-58) | 37 (16-57) | 37 (16-66) | .25 | .04 | ||
| Donors | 35 (5-65) | 35 (10-59) | 37 (14-67) | .81 | .008 | ||
| Patient sex (%) | |||||||
| Male | 138 (53) | 126 (49) | 189 (52) | ||||
| Female | 120 (46) | 130 (51) | 174 (48) | .33 | .73 | ||
| Donor sex (%) | |||||||
| Male | 128 (51) | 146 (58) | 203 (56) | ||||
| Female | 124 (49) | 104 (42) | 162 (44) | .08 | .24 | ||
| Female donor to male recipient, % | 27 | 18 | 24 | .02 | .43 | ||
| White blood cell count at diagnosis, × 109/L | 11 (0.2-420) | 10.6 (0.7-500) | 13.5 (0.7-710) | .57 | .49 | ||
| FAB classification (%) | |||||||
| M0 | 3 (1) | 1 (0.4) | 3 (1) | ||||
| M1 | 46 (20) | 53 (23) | 52 (16) | ||||
| M2 | 67 (29) | 84 (36) | 111 (34) | ||||
| M3 | 13 (5) | 9 (4) | 11 (3) | .23 | .66 | ||
| M4 | 58 (25) | 46 (20) | 81 (25) | ||||
| M5 | 37 (16) | 29 (12) | 52 (16) | ||||
| M6 | 6 (2) | 10 (4) | 13 (4) | ||||
| M7 | 4 (2) | 1 (0.4) | 4 (1) | ||||
| Cytogenetics, n (%) | n = 125 | n = 115 | n = 126 | — | — | ||
| Good | 21 (17) | 15 (13) | 21 (17) | — | — | ||
| Intermediate | 95 (76) | 93 (81) | 96 (76) | — | — | ||
| Poor | 9 (7) | 7 (6) | 9 (7) | .65 | 1 | ||
| Interval diagnosis-CR1, d (range) | 40 (12-305) | 43 (17-480) | 41 (17-432) | .34 | .96 | ||
| Interval CR1-transplantation, d (range) | 99 (13-369) | 94 (11-2375) | 97 (12-594) | .29 | .37 | ||
| TBI, % | 45 | 57 | 37 | .005 | .06 | ||
| NCs infused, × 108/kg (range) | 2 (0.17-2.7) | 3.68 (2.7-29) | 9.3 (2.2-77) | — | — | ||
| aGVHD grades II-IV, % | 38 | 35 | 36 | .5 | .61 | ||
| aGVHD grades III-IV, % | 13 | 9 | 12 | .18 | .64 | ||
| Follow-up, mo (range) | 33 (1-79) | 35 (1-81) | 16 (1-72) | — | — | ||
NC indicates nucleated cells; —, not applicable.